# Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

> **NCT00985530** · PHASE1 · TERMINATED · sponsor: **Northwestern University** · enrollment: 4 (actual)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** Tamibarotene
- **DRUG:** Arsenic trioxide

## Key facts

- **NCT ID:** NCT00985530
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Supporting agency withdrew funding for study.
- **Last updated:** 2013-10-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985530, "Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00985530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*